News Matchpoint scores $150m for I&I drugs, and other financings Matchpoint has closed a $150m round for its immunology-focused covalent drugs, with KymaThera, Rouge, Sensible Bio, and Arboretum also raising funds.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.